Compare BMEA & DWSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMEA | DWSN |
|---|---|---|
| Founded | 2017 | 1952 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.7M | 113.3M |
| IPO Year | 2021 | 1995 |
| Metric | BMEA | DWSN |
|---|---|---|
| Price | $1.52 | $3.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.86 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 277.4K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.19 | 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $145,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $1.08 |
| 52 Week High | $3.07 | $5.54 |
| Indicator | BMEA | DWSN |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 47.93 |
| Support Level | $1.22 | $1.64 |
| Resistance Level | $1.66 | $5.25 |
| Average True Range (ATR) | 0.13 | 0.63 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 86.54 | 32.82 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Dawson Geophysical Co is a provider of onshore seismic data acquisition services with operations throughout the continental United States and Canada. The company acquires and processes 2 D, 3 D, and multi-component seismic data for clients, ranging from oil and gas companies to independent oil and gas operators for use in the onshore drilling and production of oil and natural gas as well as provides multi-client data libraries. It operates through a single segment being Contract seismic data acquisition and processing services. In addition, the company provides multi-component seismic data surveys which involve the recording of alternative seismic waves. Geographically, it generates maximum revenue from the United States.